,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,940,1,2,,26630708,51081,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
1,1422,1,1,,26630708,51081,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
2,2240,1,1,,85788958,51081,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
3,2241,1,1,,85788958,51081,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
4,2275,1,1,,85788958,51081,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
5,2313,1,1,,85788958,51081,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
6,2322,1,1,,85788958,51081,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
7,2330,1,1,,85788958,51081,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
8,17991,3,3,,103174312,51081,Unspecified,,,,,Bioavailability,Other,12873497.0,
9,20922,5,3,,103174312,51081,Unspecified,,,,,Compound was evaluated for aqueous solubility at pH 7.2,Other,1311762.0,
10,40783,7,2,,103174312,51081,Unspecified,,,,,In vitro inhibition of growth of Bacillus subtilis (ATCC 6633),Other,3275778.0,
11,51918,7,2,,103174312,51081,Unspecified,,,,,Mammalian cell cytotoxicity test in chinese hamster V79 cells (clonogenic cytotoxicity),Other,1469702.0,
12,53314,5,1,,103174312,51081,Unspecified,,,,,In vitro inhibitory concentration which show total effect against Escherichia coli HR DNA gyrase,Other,,
13,53316,5,1,,103174312,51081,Unspecified,,,,,In vitro inhibitory concentration which show total effect against Escherichia coli HR DNA gyrase,Other,,
14,53325,6,6,,103174312,51081,Unspecified,,,,,In vitro antibacterial activity expressed as MIC against Escherichia coli HR DNA gyrase,Other,,
15,56591,4,4,,103174312,51081,Unspecified,,,,,Days of the first positive reaction in depleted mice.,Other,1732554.0,
16,56593,3,3,,103174312,51081,Unspecified,,,,,Number of mice which show positive phototoxic reaction in 5 mice,Other,1732554.0,
17,64390,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity carried out in vitro against Enterobacter cloacae VHG 84-39,Other,2498519.0,
18,64544,6,2,,103174312,51081,Unspecified,,,,,Activity was determined after peroral administration against Escherichia coli #311(MP) in mouse protection test,Other,2498519.0,
19,64545,6,2,,103174312,51081,Unspecified,,,,,Activity was determined after subcutaneous administration against Escherichia coli #311(MP) in mouse protection test,Other,2498519.0,
20,64550,7,2,,103174312,51081,Unspecified,,,,,Inhibition of growth of Escherichia coli (KC-14) upon oral administration in mice,Other,3275778.0,
21,64561,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity carried out in vitro against Escherichia coli #311(MP),Other,2498519.0,
22,64564,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity carried out in vitro against Escherichia coli ATCC 25922,Other,2498519.0,
23,64565,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity carried out in vitro against Escherichia coli MOR 84-20,Other,2498519.0,
24,65234,4,3,,103174312,51081,Unspecified,,,,,In vivo efficacy in mouse protection test in Escherichia coli Vogel administered by subcutaneous injection.,Other,1732554.0,
25,65235,4,3,,103174312,51081,Unspecified,,,,,In vivo efficacy in mouse protection test in Escherichia coli Vogel dose administered orally by gavage.,Other,1732554.0,
26,67532,7,2,,103174312,51081,Unspecified,,,,,Minimum inhibitory concentration (MIC) against gram negative bacteria Enterobacter cloacae MA-2646.,Other,1732554.0,
27,67545,8,1,,103174312,51081,Unspecified,,,,,Activity against Enterobacter aerogenes,Other,12873497.0,
28,67922,3,3,,103174312,51081,Unspecified,,,,,Antibacterial activity evaluated against Enterococcus faecalis,Other,15163198.0,
29,68850,6,2,,103174312,51081,Unspecified,,,,,In vitro minimum inhibitory concentration against growth of Escherichia coli Vogel,Other,6381730.0,
30,69597,3,3,,103174312,51081,Unspecified,,,,,Antibacterial activity was evaluated against Escherichia coli,Other,15163198.0,
31,69782,6,3,,103174312,51081,Unspecified,,,,,Antibacterial activity against Escherichia coli (H560),Other,3005575.0,
32,69784,6,3,,103174312,51081,Unspecified,,,,,Antibacterial activity against Escherichia coli (vogel),Other,3005575.0,
33,70411,6,2,,103174312,51081,Unspecified,,,,,In vitro for antibacterial activity against Gram-negative Escherichia coli NIJH JC-2.,Other,7452690.0,
34,70570,6,2,,103174312,51081,Unspecified,,,,,Compound was tested for inhibition of the gram-negative organism Escherichia coli H560,Other,3007757.0,
35,70571,6,2,,103174312,51081,Unspecified,,,,,Compound was tested for inhibition of the gram-negative organism Escherichia coli vogel,Other,3007757.0,
36,70704,7,2,,103174312,51081,Unspecified,,,,,Minimum inhibitory concentration (MIC) against gram negative bacteria Escherichia coli H-560.,Other,1732554.0,
37,70705,7,2,,103174312,51081,Unspecified,,,,,Minimum inhibitory concentration (MIC) against gram negative bacteria Escherichia coli Vogel.,Other,1732554.0,
38,70751,7,2,,103174312,51081,Unspecified,,,,,In vitro Inhibition of growth of Escherichia coli(KC-14),Other,3275778.0,
39,70860,6,3,,103174312,51081,Unspecified,,,,,Compound was tested for inhibition of the gram-negative organism Escherichia cloacae HA 2646,Other,3007757.0,
40,74727,7,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against five Gram-negative bacteria,Other,1469702.0,
41,74853,7,3,,103174312,51081,Unspecified,,,,,Antibacterial activity against five Gram-positive bacteria targeting topoisomerase II (DNA gyrase B GyrB),Other,1469702.0,
42,78688,6,5,,103174312,51081,Unspecified,,,,,Inhibitory concentration in supercoiling inhibition Escherichia coli DNA gyrase assay,Other,3005575.0,
43,78707,6,4,,103174312,51081,Unspecified,,,,,MIC at which cleaved DNA (linear) is observed at an intensity relative to oxolinic acid at 10 ug/mL by using Gyrase Induced DNA-Cleavage assay,Other,3005575.0,
44,78709,5,1,,103174312,51081,Unspecified,,,,,Inhibition of DNA gyrase of Escherichia coli H560 cells,Other,3007757.0,
45,94278,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity carried out in vitro against Klebsiella pneumoniae CMC 84-31,Other,2498519.0,
46,95531,7,2,,103174312,51081,Unspecified,,,,,Minimum inhibitory concentration (MIC) against gram negative bacteria Klebsiella pneumoniae MGH-2.,Other,1732554.0,
47,95885,6,3,,103174312,51081,Unspecified,,,,,Antibacterial activity against Klebsiella pneumonia (MGH-2),Other,3005575.0,
48,95889,7,2,,103174312,51081,Unspecified,,,,,In vitro inhibition of growth of Klebsiella pneumoniae (PC-1602),Other,3275778.0,
49,96229,6,2,,103174312,51081,Unspecified,,,,,Compound was tested for inhibition of the gram-negative organism Klebsiella pneumoniae MGH-2,Other,3007757.0,
50,96422,6,2,,103174312,51081,Unspecified,,,,,In vitro minimum inhibitory concentration against growth of Klebsiella pneumoniae strain 39645,Other,6381730.0,
51,117861,6,1,,103174312,51081,Unspecified,,,,,Dose required to induce phototoxic reaction in 50% of mice by probit method at different dosage forms.,Other,1732554.0,
52,122563,6,1,,103174312,51081,Unspecified,,,,,Dose which has no effect to induce phototoxic reaction in 50% of mice by probit method.,Other,1732554.0,
53,133761,4,3,,103174312,51081,Unspecified,,,,,Maximum tolerance dose was measured for phototoxic skin reaction by po administration,Other,1732554.0,
54,133805,3,4,,103174312,51081,Unspecified,,,,,Antibacterial activity in mice after intraperitoneal administration with 0.5 mL of Escherichia coli Vogel inoculum,Other,6381730.0,
55,133806,3,3,,103174312,51081,Unspecified,,,,,Compound was evaluated for antibacterial activity in mice after peroral administration with 0.5 mL of Escherichia coli Vogel inoculum,Other,6381730.0,
56,133807,3,3,,103174312,51081,Unspecified,,,,,Compound was evaluated for protective dose against Streptococcus pneumoniae SV-1 lethal infection following sc administration,Other,3007757.0,
57,133810,3,3,,103174312,51081,Unspecified,,,,,Compound was evaluated for protective dose against the Escherichia coli vogel lethal infection following peroral administration in mouse,Other,3007757.0,
58,133812,3,3,,103174312,51081,Unspecified,,,,,Compound was evaluated for protective dose against the Escherichia coli vogel lethal infection following sc administration in mouse,Other,3007757.0,
59,133813,3,3,,103174312,51081,Unspecified,,,,,Compound was evaluated for protective dose against the Streptococcus aureus UC-76 lethal infection following po administration in mouse,Other,3007757.0,
60,133815,3,3,,103174312,51081,Unspecified,,,,,Compound was evaluated for protective dose against the Streptococcus aureus UC-76 lethal infection following sc administration in mouse,Other,3007757.0,
61,133817,3,3,,103174312,51081,Unspecified,,,,,Compound was evaluated for protective dose against the Streptococcus pneumoniae SV-1 lethal infection following po administration,Other,3007757.0,
62,135327,6,1,,103174312,51081,Unspecified,,,,,BBB penetration classification,Other,10841799.0,
63,151531,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity carried out in vitro against Pseudomonas aeruginosa K84-16,Other,2498519.0,
64,161378,7,2,,103174312,51081,Unspecified,,,,,Minimum inhibitory concentration (MIC) against gram negative bacteria Prot. rettgeri M-1771.,Other,1732554.0,
65,162778,6,2,,103174312,51081,Unspecified,,,,,In vitro minimum inhibitory concentration against growth of Pseudomonas aeruginosa MGH-2,Other,6381730.0,
66,163386,7,2,,103174312,51081,Unspecified,,,,,In vitro inhibition of growth of Proteus vulgaris(OX-19),Other,3275778.0,
67,163738,6,2,,103174312,51081,Unspecified,,,,,Compound was tested for inhibition of the gram-negative organism Providencia rettgeri H1771,Other,3007757.0,
68,163914,4,3,,103174312,51081,Unspecified,,,,,In vivo efficacy (s.c.) against Pseudomonas aeruginosa in mouse protection test,Other,1732554.0,
69,163915,4,3,,103174312,51081,Unspecified,,,,,In vivo efficacy (orally) against Pseudomonas aeruginosa in mouse protection test,Other,1732554.0,
70,163916,7,2,,103174312,51081,Unspecified,,,,,Minimum inhibitory concentration (MIC) against gram negative bacteria Pseudomonas aeruginosa UI-18.,Other,1732554.0,
71,164231,3,3,,103174312,51081,Unspecified,,,,,Antibacterial activity was evaluated against Pseudomonas aeruginosa,Other,15163198.0,
72,164385,6,3,,103174312,51081,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa (UI-18),Other,3005575.0,
73,164550,6,2,,103174312,51081,Unspecified,,,,,In vitro antibacterial activity against Gram-negative Pseudomonas aeruginosa V-1.,Other,7452690.0,
74,164709,6,2,,103174312,51081,Unspecified,,,,,Compound was tested for inhibition of the gram-negative organism Pseudomonas aeruginosa UI-18,Other,3007757.0,
75,165223,7,2,,103174312,51081,Unspecified,,,,,In vitro inhibition of growth of Pseudomonas aeruginosa(E-2),Other,3275778.0,
76,201072,6,2,,103174312,51081,Unspecified,,,,,Activity was determined after peroral administration against Staphylococcus aureus Smith(MP) in mouse protection test,Other,2498519.0,
77,201073,6,2,,103174312,51081,Unspecified,,,,,Activity was determined after subcutaneous administration against Staphylococcus aureus Smith(MP) in mouse protection test,Other,2498519.0,
78,201082,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity carried out in vitro against Staphylococcus aureus ATCC 29213,Other,2498519.0,
79,201083,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity carried out in vitro against Staphylococcus aureus K82-26,Other,2498519.0,
80,201084,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity carried out in vitro against Staphylococcus aureus Smith(MP),Other,2498519.0,
81,201085,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity carried out in vitro against Staphylococcus aureus VGH 84-47,Other,2498519.0,
82,201575,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity carried out in vitro against Streptococcus faecalis UCI 85-30,Other,2498519.0,
83,201607,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity carried out in vitro against Serratia marcescens MOR 84-41,Other,2498519.0,
84,201952,4,3,,103174312,51081,Unspecified,,,,,In vivo efficacy (s.c.) against Streptococcus pneumoniae SV-1 in mouse protection test,Other,1732554.0,
85,201953,4,3,,103174312,51081,Unspecified,,,,,In vivo efficacy (orally) against Streptococcus pneumoniae SV-1 in mouse protection test,Other,1732554.0,
86,202110,4,3,,103174312,51081,Unspecified,,,,,In vivo efficacy (s.c.) against Streptococcus pyogenes C-203 in mouse protection test,Other,1732554.0,
87,202111,4,3,,103174312,51081,Unspecified,,,,,In vivo efficacy (orally) against Streptococcus pyogenes C-203 in mouse protection test,Other,1732554.0,
88,203106,7,2,,103174312,51081,Unspecified,,,,,Minimum inhibitory concentration (MIC) against gram positive bacteria Staphylococcus aureus H-228.,Other,1732554.0,
89,203107,7,2,,103174312,51081,Unspecified,,,,,Minimum inhibitory concentration (MIC) against gram positive bacteria Staphylococcus aureus UC-76.,Other,1732554.0,
90,203331,7,2,,103174312,51081,Unspecified,,,,,In vitro inhibition of growth of Serratia marcescens (IAM1184),Other,3275778.0,
91,205558,8,2,,103174312,51081,Unspecified,,,,,Minimum inhibitory concentration against Staphylococcus aureus AS5155,Other,12657275.0,
92,205683,8,2,,103174312,51081,Unspecified,,,,,Minimum inhibitory concentration against Staphylococcus aureus RN4220,Other,12657275.0,
93,205944,7,2,,103174312,51081,Unspecified,,,,,Minimum inhibitory concentration (MIC) against gram positive bacteria Streptococcus faecalis MGH-2.,Other,1732554.0,
94,205945,7,2,,103174312,51081,Unspecified,,,,,Minimum inhibitory concentration (MIC) against gram positive bacteria Streptococcus pneumoniae SV-1.,Other,1732554.0,
95,205946,7,2,,103174312,51081,Unspecified,,,,,Minimum inhibitory concentration (MIC) against gram positive bacteria Streptococcus pyogenes C-203.,Other,1732554.0,
96,206517,8,2,,103174312,51081,Unspecified,,,,,Minimum inhibitory concentration against Quinolone sensitive Staphylococcus hominis IP8203 Strain.,Other,11294391.0,
97,206728,3,3,,103174312,51081,Unspecified,,,,,Antibacterial activity was evaluated against Staphylococcus aureus,Other,15163198.0,
98,207175,6,3,,103174312,51081,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus (H228),Other,3005575.0,
99,207212,6,2,,103174312,51081,Unspecified,,,,,In vitro minimum inhibitory concentration against growth of Staphylococcus aureus Smith,Other,6381730.0,
100,207383,7,2,,103174312,51081,Unspecified,,,,,Inhibition of growth of Staphylococcus aureus (FDA207PJC-1) after incubation at 37 degree Centigrade,Other,3275778.0,
101,207705,8,2,,103174312,51081,Unspecified,,,,,Minimum inhibitory concentration against Quinolone Resistant Staphylococcus aureus LF11C128B Strain.,Other,11294391.0,
102,207933,6,2,,103174312,51081,Unspecified,,,,,"In vitro antibacterial activity against Gram-positive, Staphylococcus aureus 209 P",Other,7452690.0,
103,208893,6,3,,103174312,51081,Unspecified,,,,,Compound was tested for inhibition of the gram-negative organism Streptococcus aureus H228.,Other,3007757.0,
104,208894,6,3,,103174312,51081,Unspecified,,,,,Compound was tested for inhibition of the gram-negative organism Streptococcus aureus UC-76.,Other,3007757.0,
105,209087,6,2,,103174312,51081,Unspecified,,,,,Compound was tested for inhibition of the gram-negative organism Streptococcus faecalis MGH-2,Other,3007757.0,
106,209302,6,2,,103174312,51081,Unspecified,,,,,Compound was tested for inhibition of the gram-negative organism Streptococcus pyogenes C203.,Other,3007757.0,
107,209766,8,2,,103174312,51081,Unspecified,,,,,Minimum inhibitory concentration against Streptococcus pyogenes Dig 7,Other,12657275.0,
108,210022,6,3,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae (SV-1),Other,3005575.0,
109,210196,6,2,,103174312,51081,Unspecified,,,,,Compound was tested for inhibition of the gram-negative organism Streptococcus pneumoniae SV-1,Other,3007757.0,
110,237034,3,4,,103174312,51081,Unspecified,,,,,Dissociation constant (pKa) was determined,Other,16078842.0,
111,237037,3,4,,103174312,51081,Unspecified,,,,,Dissociation constant (pKa) was determined,Other,16078842.0,
112,237457,3,5,,103174312,51081,Unspecified,,,,,Partition coefficient (logD2.0),Other,16078842.0,
113,237458,3,5,,103174312,51081,Unspecified,,,,,Partition coefficient (logD7.4),Other,16078842.0,
114,244871,6,2,,103174312,51081,Unspecified,,,,,In vitro antibacterial activity against Escherichia coli NIHJ JC-2,Other,15857152.0,
115,244878,6,2,,103174312,51081,Unspecified,,,,,In vitro antibacterial activity against Staphylococcus aureus Smith,Other,15857152.0,
116,244897,6,2,,103174312,51081,Unspecified,,,,,In vitro antibacterial activity against Pseudomonas aeruginosa IID1210,Other,15857152.0,
117,244930,6,2,,103174312,51081,Unspecified,,,,,In vitro antibacterial activity against Streptococcus pneumoniae type III,Other,15857152.0,
118,324745,6,4,,103174312,51081,Unspecified,,,,,Inhibition of Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as inhibition of pBR322 DNA supercoiling,Other,17325221.0,
119,324746,5,1,,103174312,51081,Unspecified,,,,,Effect on Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as enhancement of supercoiled pBR322 DNA cleavage,Other,17325221.0,
120,324747,3,5,,103174312,51081,Unspecified,,,,,Antibacterial activity against Mycobacterium leprae at 5 ug/mL after 11 to 18 days,Other,17325221.0,
121,324752,3,7,,103174312,51081,Unspecified,,,,,Antibacterial activity in Mycobacterium leprae infected mouse foot-pad model assessed as parasite killing at >300 mg/kg/day after 9 months,Other,17325221.0,
122,405454,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Escherichia coli C600Rif by Etest,Other,17470656.0,
123,405456,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Escherichia coli C600Rif in presence of 40 ug/ml efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine by Etest,Other,17470656.0,
124,405457,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Escherichia coli C600Rif in presence of 50 ug/ml efflux pump inhibitor phenyl-arginine-beta-naphthylamide by Etest,Other,17470656.0,
125,405458,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Escherichia coli C600Rif containing pIP1206 plasmid by Etest,Other,17470656.0,
126,405459,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Escherichia coli C600Rif containing pIP1206 plasmid in presence of 40 ug/ml efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine by Etest,Other,17470656.0,
127,405460,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Escherichia coli C600Rif containing pIP1206 plasmid in presence of 50 ug/ml efflux pump inhibitor phenyl-arginine-beta-naphthylamide by Etest,Other,17470656.0,
128,405461,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Escherichia coli TOP10 by Etest,Other,17470656.0,
129,405462,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Escherichia coli TOP10 in presence of 40 ug/ml efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine by Etest,Other,17470656.0,
130,405463,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Escherichia coli TOP10 in presence of 50 ug/ml efflux pump inhibitor phenyl-arginine-beta-naphthylamide by Etest,Other,17470656.0,
131,405464,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Escherichia coli TOP10 containing pIP1206 plasmid by Etest,Other,17470656.0,
132,405465,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Escherichia coli TOP10 containing pIP1206 plasmid in presence of 40 ug/ml efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine by Etest,Other,17470656.0,
133,405466,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Escherichia coli TOP10 containing pIP1206 plasmid in presence of 50 ug/ml efflux pump inhibitor phenyl-arginine-beta-naphthylamide by Etest,Other,17470656.0,
134,405467,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Escherichia coli TOP10 containing pAT851 plasmid by Etest,Other,17470656.0,
135,405468,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Escherichia coli TOP10 containing pAT851 in presence of 40 ug/ml efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine by Etest,Other,17470656.0,
136,405469,6,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Escherichia coli TOP10 containing pAT851 in presence of 50 ug/ml efflux pump inhibitor phenyl-arginine-beta-naphthylamide by Etest,Other,17470656.0,
137,411793,6,2,,103174312,51081,Unspecified,,,,,Metabolic stability in human liver microsomes assessed as intrinsic clearance per mg of protein,Other,19108654.0,
138,425652,7,2,,103174312,51081,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
139,425653,7,2,,103174312,51081,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
140,428290,7,2,,103174312,51081,Unspecified,,,,,Antimicrobial activity against Acinetobacter baumannii BM4454 isolated from patient with urinary tract infection by E test,Other,18086852.0,
141,428291,7,2,,103174312,51081,Unspecified,,,,,Antimicrobial activity against Acinetobacter baumannii BM4652 expressing adeABC adeIJK double mutant isolated from patient with urinary tract infection by E test,Other,18086852.0,
142,428292,7,2,,103174312,51081,Unspecified,,,,,Antimicrobial activity against Acinetobacter baumannii BM4579 expressing deltaadeIJK genes isolated from patient with urinary tract infection by E test,Other,18086852.0,
143,428293,7,2,,103174312,51081,Unspecified,,,,,Antimicrobial activity against Acinetobacter baumannii BM4651 expressing deltaadeIJK genes isolated from patient with urinary tract infection by E test,Other,18086852.0,
144,428294,7,2,,103174312,51081,Unspecified,,,,,Antimicrobial activity against Acinetobacter baumannii BM4652 expressing adeIJK genes with pAT807 isolated from patient with urinary tract infection by E test,Other,18086852.0,
145,428295,7,2,,103174312,51081,Unspecified,,,,,Antimicrobial activity against Acinetobacter baumannii BM4579 expressing adeIJK genes with pAT807 isolated from patient with urinary tract infection by agar dilution method,Other,18086852.0,
146,430760,6,2,,103174312,51081,Unspecified,,,50.0,IC50,"Antiresorptive activity against 1,25-dihydroxyvitamine D3-stimulated osteoclast formation in Swiss Webster mouse bone marrow cells assessed as reduction of tartrate-resistant acid phosphatase activity after 7 days",Confirmatory,19630402.0,
147,434959,1,1,,85788958,51081,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
148,444050,7,1,,103174312,51081,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
149,444051,6,2,,103174312,51081,Unspecified,,,,,Total clearance in human,Other,20070106.0,
150,444052,6,2,,103174312,51081,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
151,444053,6,2,,103174312,51081,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
152,444054,6,1,,103174312,51081,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
153,444055,3,3,,103174312,51081,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
154,444056,3,3,,103174312,51081,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
155,444057,3,3,,103174312,51081,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
156,444058,6,2,,103174312,51081,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
157,445445,7,1,,103174312,51081,Unspecified,,,,,Permeability at pH 6.5 by PAMPA method,Other,19947605.0,
158,445446,3,4,,103174312,51081,Unspecified,,,,,Oral bioavailability in human,Other,19947605.0,
159,450457,3,4,,103174312,51081,Active,,,,,Antibacterial activity against Staphylococcus aureus after 24 hrs by twofold serial dilution method,Other,19581101.0,
160,450458,3,4,,103174312,51081,Active,,,,,Antibacterial activity against Bacillus subtilis after 24 hrs by twofold serial dilution method,Other,19581101.0,
161,450459,3,4,,103174312,51081,Active,,,,,Antibacterial activity against Serratia marcescens after 24 hrs by twofold serial dilution method,Other,19581101.0,
162,450460,3,4,,103174312,51081,Active,,,,,Antibacterial activity against Pseudomonas aeruginosa after 24 hrs by twofold serial dilution method,Other,19581101.0,
163,450461,3,4,,103174312,51081,Active,,,,,Antibacterial activity against Escherichia coli after 24 hrs by twofold serial dilution method,Other,19581101.0,
164,476929,3,3,,103174312,51081,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
165,485350,1,2,,92223552,51081,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
166,485395,1,2,,92223552,51081,Inactive,150392496.0,,,,A screen for compounds that inhibit the activity of Staphylococcus aureus DNA helicase,Other,,
167,492967,1,2,,92223552,51081,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
168,493033,1,2,,92223552,51081,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
169,497756,2,4,,103174312,51081,Unspecified,,,,,"Distribution coefficient, log D of the compound",Other,19822706.0,
170,497757,5,1,,103174312,51081,Unspecified,,,,,Apparent permeability across apical to basolateral side in human Calu3 cells,Other,19822706.0,
171,497758,5,1,,103174312,51081,Unspecified,,,,,Apparent permeability across basolateral to apical side in human Calu3 cells,Other,19822706.0,
172,497759,2,3,,103174312,51081,Unspecified,,,,,Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Calu3 cells,Other,19822706.0,
173,497760,5,1,,103174312,51081,Unspecified,,,,,Apparent permeability across apical to basolateral side in human Calu3 cells in presence of 3 uM PSC-833 P-gp inhibitor,Other,19822706.0,
174,497761,5,1,,103174312,51081,Unspecified,,,,,Apparent permeability across basolateral to apical side in human Calu3 cells in presence of 3 uM PSC-833 P-gp inhibitor,Other,19822706.0,
175,497762,2,3,,103174312,51081,Unspecified,,,,,Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Calu3 cells in presence of 3 uM PSC-833 P-gp inhibitor,Other,19822706.0,
176,498872,5,2,,103174312,51081,Unspecified,,,,,Antimicrobial activity against Acinetobacter baumannii B9 containing carbapenemase blaOXA-23 gene assessed as growth inhibition by Etest method,Other,19884362.0,
177,504770,1,2,,92223552,51081,Active,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
178,530345,5,2,,103174312,51081,Unspecified,,,,,"Antimicrobial activity against Escherichia coli BicA expressing blaTEM-1, blaCTX-M-15 and qepA2 gene by disk diffusion method",Other,18644958.0,
179,530346,5,2,,103174312,51081,Unspecified,,,,,Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M plasmid carrying blaCTX-M-15 gene by disk diffusion method,Other,18644958.0,
180,530347,5,2,,103174312,51081,Unspecified,,,,,Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M carrying blaCTX-M-15 and pQep plasmid carrying qepA2 gene by disk diffusion method,Other,18644958.0,
181,530348,5,2,,103174312,51081,Unspecified,,,,,Antimicrobial activity against azide-resistant Escherichia coli J53 by disk diffusion method,Other,18644958.0,
182,530349,5,2,,103174312,51081,Unspecified,,,,,Antimicrobial activity against Escherichia coli TOP10 harboring pQep plasmid carrying qepA2 gene by disk diffusion method,Other,18644958.0,
183,530350,5,2,,103174312,51081,Unspecified,,,,,Antimicrobial activity against Escherichia coli TOP10 by disk diffusion method,Other,18644958.0,
184,540209,4,3,,103174312,51081,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
185,540210,4,3,,103174312,51081,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
186,540211,2,5,,103174312,51081,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
187,540212,4,3,,103174312,51081,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
188,540213,4,3,,103174312,51081,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
189,540230,2,5,,103174312,51081,Unspecified,,,,,Dose normalised AUC in rat after po administration,Other,16019946.0,
190,540231,2,5,,103174312,51081,Unspecified,,,,,Dose normalised AUC in dog after po administration,Other,16019946.0,
191,540232,2,5,,103174312,51081,Unspecified,,,,,Dose normalised AUC in monkey after po administration,Other,16019946.0,
192,540233,2,5,,103174312,51081,Unspecified,,,,,Dose normalised AUC in human after po administration,Other,16019946.0,
193,540299,1,2,,92223552,51081,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
194,544831,2,4,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae CIP104485 by agar disk diffusion method,Other,18725440.0,
195,544832,2,6,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae R6 by agar disk diffusion method,Other,18725440.0,
196,544833,2,4,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae CP1000 by agar disk diffusion method,Other,18725440.0,
197,544834,2,6,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae R6 Tr6 harboring gyrA Ser81Phe mutant gene by agar disk diffusion method,Other,18725440.0,
198,544835,2,4,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1686 harboring gyrA Glu85Lys mutant gene by agar disk diffusion method,Other,18725440.0,
199,544836,2,4,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1050 harboring gyrA Ser81Phe mutant gene by agar disk diffusion method,Other,18725440.0,
200,544837,2,4,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1051 harboring gyrA Ser81Tyr mutant gene by agar disk diffusion method,Other,18725440.0,
201,544838,2,4,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1266 harboring gyrA Ser81Cys mutant gene by agar disk diffusion method,Other,18725440.0,
202,544839,2,4,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae H548 clinical isolate harboring gyrA Ser81Phe mutant gene by agar disk diffusion method,Other,18725440.0,
203,544840,2,6,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae R6 Tr1 harboring parC Ser79Tyr mutant gene by agar disk diffusion method,Other,18725440.0,
204,544841,2,4,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1053 harboring parC Ser79Phe mutant gene by agar disk diffusion method,Other,18725440.0,
205,544842,2,4,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1413 harboring parC Ser79Tyr mutant gene by agar disk diffusion method,Other,18725440.0,
206,544843,2,4,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1693 harboring parC Asp83Asn mutant gene by agar disk diffusion method,Other,18725440.0,
207,544844,2,4,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1411 harboring parC Asp83Gly mutant gene by agar disk diffusion method,Other,18725440.0,
208,544845,2,4,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1681 harboring parC Ser79Tyr Asp83Ala mutant gene by agar disk diffusion method,Other,18725440.0,
209,544846,2,6,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae R6 Tr10 harboring gyrA Ser81Tyr parC Ser79Tyr mutant gene by agar disk diffusion method,Other,18725440.0,
210,544847,2,4,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1056 harboring gyrA Ser81Tyr parC Asp83His mutant gene by agar disk diffusion method,Other,18725440.0,
211,544848,2,4,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1060 harboring gyrA Ser81Phe parC Asp83His mutant gene by agar disk diffusion method,Other,18725440.0,
212,544849,2,4,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1414 harboring gyrA Glu85Lys parC Ser79Phe mutant gene by agar disk diffusion method,Other,18725440.0,
213,544850,5,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae CIP104485 by agar dilution method,Other,18725440.0,
214,544851,5,4,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae R6 by agar dilution method,Other,18725440.0,
215,544852,5,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae CP1000 by agar dilution method,Other,18725440.0,
216,544853,5,4,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae R6 Tr6 harboring gyrA Ser81Phe mutant gene by agar dilution method,Other,18725440.0,
217,544854,5,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1686 harboring gyrA Glu85Lys mutant gene by agar dilution method,Other,18725440.0,
218,544855,5,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1050 harboring gyrA Ser81Phe mutant gene by agar dilution method,Other,18725440.0,
219,544856,5,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1051 harboring gyrA Ser81Tyr mutant gene by agar dilution method,Other,18725440.0,
220,544857,5,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1266 harboring gyrA Ser81Cys mutant gene by agar dilution method,Other,18725440.0,
221,544858,5,2,,103174312,51081,Inconclusive,,,,,Antibacterial activity against Streptococcus pneumoniae H548 clinical isolate harboring gyrA Ser81Phe mutant gene by agar dilution method,Other,18725440.0,
222,544859,5,4,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae R6 Tr1 harboring parC Ser79Tyr mutant gene by agar dilution method,Other,18725440.0,
223,544860,5,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1053 harboring parC Ser79Phe mutant gene by agar dilution method,Other,18725440.0,
224,544861,5,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1413 harboring parC Ser79Tyr mutant gene by agar dilution method,Other,18725440.0,
225,544862,5,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1693 harboring parC Asp83Asn mutant gene by agar dilution method,Other,18725440.0,
226,544863,5,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1411 harboring parC Asp83Gly mutant gene by agar dilution method,Other,18725440.0,
227,544864,5,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1681 harboring parC Ser79Tyr Asp83Ala mutant gene by agar dilution method,Other,18725440.0,
228,544865,5,4,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae R6 Tr10 harboring gyrA Ser81Tyr parC Ser79Tyr mutant gene by agar dilution method,Other,18725440.0,
229,544866,5,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1056 harboring gyrA Ser81Tyr parC Asp83His mutant gene by agar dilution method,Other,18725440.0,
230,544867,5,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1060 harboring gyrA Ser81Phe parC Asp83His mutant gene by agar dilution method,Other,18725440.0,
231,544868,5,2,,103174312,51081,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae U2A1414 harboring gyrA Glu85Lys parC Ser79Phe mutant gene by agar dilution method,Other,18725440.0,
232,588519,1,2,,92223552,51081,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
233,624101,1,2,,85788958,51081,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
234,624136,1,1,,85788958,51081,Inactive,208342286.0,7157.0,,,mutant P53 Measured in Biochemical System Using Small Molecule MicroArray - 2077-01_Other_SinglePoint_HTS_Activity,Screening,,
235,624137,1,1,,85788958,51081,Inactive,881546.0,3400.0,,,SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity,Screening,,
236,624138,1,1,,85788958,51081,Inactive,21618340.0,6774.0,,,SMM STAT-3 Measured in Biochemical System Using Small Molecule MicroArray - 2076-01_Other_SinglePoint_HTS_Activity_Set2,Screening,,
237,624139,1,1,,85788958,51081,Inactive,34577122.0,4790.0,,,NF-KappaB Measured in Biochemical System Using Small Molecule MicroArray - 2080-01_Other_SinglePoint_HTS_Activity,Screening,,
238,624141,1,1,,85788958,51081,Inactive,71774083.0,4609.0,,,SMM c-myc Measured in Biochemical System Using Small Molecule MicroArray - 2081-01_Other_SinglePoint_HTS_Activity,Screening,,
239,624151,1,1,,85788958,51081,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,Screening,,
240,624156,1,1,,85788958,51081,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
241,624260,1,1,,85788958,51081,Inactive,109633019.0,7468.0,,,NSD2 Inhibitors Measured in Biochemical System Using Plate Reader - 2115-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
242,624349,1,2,,92309145,51081,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
243,625144,5,5,,103174312,51081,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
244,625145,4,7,,103174312,51081,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
245,625146,5,5,,103174312,51081,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
246,625147,4,7,,103174312,51081,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
247,625148,4,7,,103174312,51081,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
248,625149,4,7,,103174312,51081,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
249,625150,5,5,,103174312,51081,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
250,625151,4,7,,103174312,51081,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
251,625152,4,7,,103174312,51081,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
252,625153,4,7,,103174312,51081,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
253,625154,4,7,,103174312,51081,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
254,625155,4,7,,103174312,51081,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
255,625156,1,9,,103174312,51081,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
256,625157,6,2,,103174312,51081,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
257,625158,3,4,,103174312,51081,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
258,625159,5,5,,103174312,51081,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
259,625160,1,9,,103174312,51081,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
260,625161,4,7,,103174312,51081,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
261,625162,4,7,,103174312,51081,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
262,625163,4,7,,103174312,51081,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
263,625164,1,6,,103174312,51081,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
264,625165,3,4,,103174312,51081,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
265,625166,3,4,,103174312,51081,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
266,625167,5,5,,103174312,51081,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
267,625168,4,7,,103174312,51081,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
268,625169,1,6,,103174312,51081,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
269,625170,3,4,,103174312,51081,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
270,625171,4,7,,103174312,51081,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
271,625172,4,7,,103174312,51081,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
272,625173,5,5,,103174312,51081,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
273,625174,5,5,,103174312,51081,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
274,625175,5,5,,103174312,51081,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
275,625176,1,9,,103174312,51081,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
276,625177,5,5,,103174312,51081,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
277,625178,5,5,,103174312,51081,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
278,625179,1,9,,103174312,51081,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
279,625180,5,5,,103174312,51081,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
280,625181,5,5,,103174312,51081,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
281,625182,5,5,,103174312,51081,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
282,625183,5,5,,103174312,51081,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
283,625184,5,5,,103174312,51081,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
284,625185,5,5,,103174312,51081,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
285,625186,5,5,,103174312,51081,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
286,625187,5,5,,103174312,51081,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
287,625188,1,9,,103174312,51081,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
288,625189,1,7,,103174312,51081,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
289,625190,4,5,,103174312,51081,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
290,625191,4,7,,103174312,51081,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
291,625192,4,7,,103174312,51081,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
292,625193,5,5,,103174312,51081,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
293,625194,4,7,,103174312,51081,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
294,625195,4,7,,103174312,51081,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
295,625196,5,6,,103174312,51081,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
296,625197,3,4,,103174312,51081,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
297,625198,4,7,,103174312,51081,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
298,625199,4,7,,103174312,51081,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
299,625200,4,7,,103174312,51081,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
300,625201,4,7,,103174312,51081,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
301,625202,4,7,,103174312,51081,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
302,625203,4,7,,103174312,51081,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
303,625204,4,7,,103174312,51081,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
304,625205,4,7,,103174312,51081,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
305,625206,4,7,,103174312,51081,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
306,625207,4,7,,103174312,51081,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
307,625208,5,5,,103174312,51081,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
308,625209,4,7,,103174312,51081,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
309,625210,3,4,,103174312,51081,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
310,625211,1,6,,103174312,51081,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
311,625212,3,4,,103174312,51081,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
312,625213,4,7,,103174312,51081,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
313,625214,1,9,,103174312,51081,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
314,625215,3,4,,103174312,51081,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
315,625216,3,4,,103174312,51081,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
316,625217,4,7,,103174312,51081,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
317,625218,4,7,,103174312,51081,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
318,625219,3,4,,103174312,51081,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
319,625220,4,7,,103174312,51081,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
320,625221,4,7,,103174312,51081,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
321,625222,4,7,,103174312,51081,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
322,625223,4,7,,103174312,51081,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
323,625224,3,4,,103174312,51081,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
324,625225,3,4,,103174312,51081,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
325,625226,4,7,,103174312,51081,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
326,625227,4,7,,103174312,51081,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
327,625228,4,7,,103174312,51081,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
328,625229,5,5,,103174312,51081,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
329,625230,1,6,,103174312,51081,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
330,625231,4,7,,103174312,51081,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
331,625232,1,9,,103174312,51081,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
332,625233,4,7,,103174312,51081,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
333,625234,3,4,,103174312,51081,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
334,625235,4,7,,103174312,51081,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
335,625236,5,5,,103174312,51081,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
336,625237,4,7,,103174312,51081,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
337,625238,4,7,,103174312,51081,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
338,625239,4,7,,103174312,51081,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
339,625240,1,9,,103174312,51081,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
340,625241,4,7,,103174312,51081,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
341,625242,4,7,,103174312,51081,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
342,625243,5,5,,103174312,51081,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
343,625244,5,5,,103174312,51081,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
344,625245,5,5,,103174312,51081,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
345,625246,1,9,,103174312,51081,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
346,625247,5,5,,103174312,51081,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
347,625248,5,5,,103174312,51081,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
348,625249,5,5,,103174312,51081,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
349,625250,5,5,,103174312,51081,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
350,625251,5,5,,103174312,51081,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
351,625252,4,7,,103174312,51081,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
352,625253,4,7,,103174312,51081,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
353,625254,4,7,,103174312,51081,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
354,625255,4,7,,103174312,51081,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
355,625256,4,7,,103174312,51081,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
356,625257,4,7,,103174312,51081,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
357,625258,4,7,,103174312,51081,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
358,625259,4,7,,103174312,51081,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
359,625260,3,4,,103174312,51081,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
360,625261,3,4,,103174312,51081,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
361,625262,3,4,,103174312,51081,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
362,625263,4,7,,103174312,51081,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
363,625264,3,4,,103174312,51081,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
364,625265,1,6,,103174312,51081,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
365,625266,3,4,,103174312,51081,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
366,625267,3,4,,103174312,51081,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
367,625268,4,2,,103174312,51081,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
368,625268,4,2,,103174312,51081,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
369,625268,4,2,,103174312,51081,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
370,625268,4,2,,103174312,51081,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
371,625269,4,7,,103174312,51081,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
372,625270,4,7,,103174312,51081,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
373,625271,5,5,,103174312,51081,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
374,625272,3,4,,103174312,51081,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
375,625273,4,6,,103174312,51081,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
376,625274,1,6,,103174312,51081,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
377,625275,3,4,,103174312,51081,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
378,651548,1,1,,85788958,51081,Inactive,21361095.0,2146.0,,,EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
379,651828,1,2,,92309145,51081,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
380,720641,1,2,,92223552,51081,Active,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
381,720641,1,2,,92309145,51081,Active,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
382,720717,1,3,,92223552,51081,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
383,720717,1,3,,92309145,51081,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
384,743344,1,1,,174006962,51081,Inactive,,,14.9502,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
385,743345,1,1,,174006962,51081,Inactive,,,16.7744,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
386,743346,1,1,,174006962,51081,Inactive,,,9.4329,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
387,743347,1,1,,174006962,51081,Inactive,,,21.1177,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
388,1079931,1,1,,103174312,51081,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
389,1079932,1,1,,103174312,51081,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
390,1079933,1,1,,103174312,51081,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
391,1079934,1,1,,103174312,51081,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
392,1079935,1,1,,103174312,51081,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
393,1079936,1,1,,103174312,51081,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
394,1079937,1,1,,103174312,51081,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
395,1079938,1,1,,103174312,51081,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
396,1079939,1,1,,103174312,51081,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
397,1079940,1,1,,103174312,51081,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
398,1079941,1,1,,103174312,51081,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
399,1079942,1,1,,103174312,51081,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
400,1079943,1,1,,103174312,51081,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
401,1079944,1,1,,103174312,51081,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
402,1079945,1,1,,103174312,51081,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
403,1079946,1,1,,103174312,51081,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
404,1079947,1,1,,103174312,51081,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
405,1079948,1,1,,103174312,51081,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
406,1079949,1,1,,103174312,51081,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
407,1159386,1,2,,103174312,51081,Unspecified,,,,,ASTRAZENECA: Most basic pKa value (pKa B1) determined by absorption and potentiometric titration using standard methodology from Sirius Analytical. Experimental range Bases: >= 2.,Other,,
408,1159399,1,2,,103174312,51081,Unspecified,,,,,ASTRAZENECA: Most acidic pKa value (pKa A1) determined by absorption and potentiometric titration using standard methodology from Sirius Analytical. Experimental range Acids: <= 11.,Other,,
409,1159580,2,1,,268735079,51081,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
410,1159607,2,1,,312310043,51081,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
411,1224824,1,1,,174006962,51081,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
412,1224825,1,1,,174006962,51081,Inactive,,,0.0332,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
413,1224857,2,1,,174006962,51081,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
414,1224859,2,1,,174006962,51081,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
415,1224863,1,1,,176484570,51081,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
416,1224863,1,1,,316919303,51081,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
417,1224905,2,1,,92223552,51081,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
418,1224905,2,1,,92223552,51081,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
419,1224905,2,1,,92309145,51081,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
420,1224905,2,1,,92309145,51081,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
421,1259252,1,1,,174006962,51081,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
422,1259253,1,1,,174006962,51081,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
423,1259255,1,1,,174006962,51081,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
424,1259256,1,1,,174006962,51081,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
425,1259310,1,1,,321943428,51081,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
426,1259310,1,1,,333233840,51081,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
427,1259325,1,2,,336954415,51081,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
428,1259370,2,2,,124665975,51081,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
429,1259370,2,2,,124665975,51081,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
430,1259370,2,2,,124665975,51081,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
431,1259389,1,1,,124665975,51081,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
432,1259407,1,1,,363906160,51081,Inactive,,,,,CCRIS mutagenicity studies,Other,,
433,1259416,1,2,,340081381,51081,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
434,1259416,1,2,,375174442,51081,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
435,1259416,1,2,,375188953,51081,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
436,1259421,1,1,,340081381,51081,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
437,1259421,1,1,,375174442,51081,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
438,1259423,1,2,,354914121,51081,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
439,1259423,1,2,,355018035,51081,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
